A5009790128- Heart Failure Treatment and Management
- Peripheral Artery Disease Management
- Lipoproteins and Cardiovascular Health
- Cardiovascular Function and Risk Factors
- Antiplatelet Therapy and Cardiovascular Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes Treatment and Management
- Congenital Heart Disease Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cerebrovascular and Carotid Artery Diseases
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Potassium and Related Disorders
- Atrial Fibrillation Management and Outcomes
- Obesity, Physical Activity, Diet
- Blood Pressure and Hypertension Studies
- Transplantation: Methods and Outcomes
- Cardiac Arrhythmias and Treatments
- Pancreatic function and diabetes
- Cardiovascular and exercise physiology
- Pharmaceutical Economics and Policy
- Healthcare Policy and Management
- Venous Thromboembolism Diagnosis and Management
- Pulmonary Hypertension Research and Treatments
- Ear Surgery and Otitis Media
- Coronary Interventions and Diagnostics
Clinical Research Institute
2017-2025
Duke University
2017-2025
Duke Medical Center
2017-2025
Canadian Respiratory Research Network
2023
Duke University Hospital
2017
Bristol-Myers Squibb (United States)
2017
Mayo Clinic
2017
Uppsala University
2017
Oslo University Hospital
2017
Although PCSK9 inhibitors (PCSK9i) were approved in 2015, their high cost has led to strict prior authorization practices and copays, use of PSCK9i clinical practice been low.To evaluate patient access PCSK9i among those prescribed therapy.Using pharmacy transaction data, we evaluated 45 029 patients who newly the United States between August 1, July 31, 2016.The proportion prescriptions abandoned (approved but unfilled); multivariable analyses examined factors associated with...
The effect of polyvascular disease on cardiovascular outcomes in the background peripheral artery (PAD) is unclear.To determine risk ischemic events (both cardiac and limb) among patients with PAD disease.In this post hoc secondary analysis international Examining Use Ticagrelor Peripheral Artery Disease (EUCLID) trial, were compared 13 885 enrolled alone, + coronary (CAD), cerebrovascular (CVD), CAD CVD. Adjusted Cox proportional hazards regression models implemented to associated outcomes,...
Vericiguat reduced the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization in patients with worsening HF ejection fraction (HFrEF) and a lower limit baseline estimated glomerular filtration rate (eGFR) 15 mL/min/1.73 m
•Averaging triglycerides (TGs) improves risk prediction over single measurements.•TGs are associated with increased cardiovascular risk, even in the "normal" range.•The association between TGs and events differs by sex. BackgroundElevated of disease (CVD), but best way to both measure assess TG-related remains unknown.ObjectiveThe objective study was evaluate CVD determine whether average a series TG measurements is more predictive than measurement.MethodsWe examined 15,792 participants,...
Background Prior studies have demonstrated a link between the metabolic syndrome and increased risk of cardiovascular mortality. Whether is associated with sudden cardiac death uncertain. Methods Results We characterized relationship status among participants ARIC (Atherosclerosis Risk in Communities) Study (1987–2012) free prevalent coronary heart disease or failure. Among 13 168 participants, 357 (2.7%) deaths occurred during median follow‐up 23.6 years. Participants (n=4444) had higher...
To examine the bi-directional associations of a weight loss intervention with quality life and mental health in obese older adults functional limitations.
Background Although safety and tolerability of vericiguat were established in the VICTORIA (Vericiguat Global Study Subjects With Heart Failure Reduced Ejection Fraction) trial patients with heart failure reduced ejection fraction, some subgroups may be more susceptible to symptomatic hypotension, such as older patients, those lower baseline systolic blood pressure (SBP), or concurrently taking angiotensin receptor neprilysin inhibitors. We described SBP trajectories over time compared...
Importance Chronic kidney disease (CKD) is an often-asymptomatic complication of type 2 diabetes (T2D) that requires annual screening to diagnose. Patient-level factors linked inadequate and treatment can inform implementation strategies facilitate guideline-recommended CKD care. Objective To identify risk for nonconcordance with in patients T2D. Design, Setting, Participants This retrospective cohort study was performed at 20 health care systems contributing data the US National...
There are important differences among guideline recommendations for using statin therapy in primary prevention. New from the US Preventive Services Task Force (USPSTF) emphasize based on presence of 1 or more cardiovascular disease (CVD) risk factors and a 10-year global CVD 10% greater.To determine difference eligibility prevention treatment adults, assuming full application USPSTF compared with American College Cardiology/American Heart Association (ACC/AHA) guidelines.National Health...
ObjectivesTo determine whether hydroxychloroquine (HCQ) is safe and effective at preventing COVID-19 infections among health care workers (HCWs).MethodsIn a 1: 1 randomized, placebo-controlled, double-blind, parallel-group, superiority trial 34 US clinical centers, 1360 HCWs risk for infection were enrolled between April November 2020. Participants randomized to HCQ or matched placebo. The dosing included loading dose of 600 mg twice on day 1, followed by 400 daily 29 days. primary outcome...
Patients with peripheral artery disease (PAD) are at high risk for myocardial infarction (MI).To characterize the incidence and types of MI in a PAD population, identify factors associated MI, determine association cardiovascular mortality acute limb ischemia.The Study Comparing Cardiovascular Effects Ticagrelor Clopidogrel With Peripheral Artery Disease (EUCLID) was double-blind randomized clinical trial conducted 811 sites 28 countries that 13 885 patients symptomatic to monotherapy...
Background: Peripheral artery disease (PAD) is associated with increased risk of mortality, cardiovascular morbidity, and major amputation. Data on amputation from a large randomized trial that included substantial cohort patients without critical limb ischemia (CLI) have not been described. The objective was to describe the incidence types amputations in EUCLID (Examining Use Ticagrelor Artery Disease) population, subcategorize CLI versus no cohorts, events surrounding Methods Results:...
Aim Pooled efficacy studies suggest that glycaemic responses to dipeptidyl‐peptidase 4 inhibitors in type 2 diabetes are greatest Asians, who may also respond better alpha‐glucosidase inhibitors. We assessed the impact of sitagliptin by race Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), and whether this was enhanced Asians concomitant acarbose therapy. Materials methods TECOS enrolled 14 671 patients diabetes, cardiovascular disease HbA1c 48–64 mmol/mol (6.5%‐8.0%),...